Compare, Analyse Glenmark Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
ADCOCK INGRAM
Jun-14
GLENMARK PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs712311-   
Low Rs484224-   
Sales per share (Unadj.) Rs349.692.5-  
Earnings per share (Unadj.) Rs32.8-23.3-  
Cash flow per share (Unadj.) Rs44.3-19.3-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs198.672.6-  
Shares outstanding (eoy) m282.17168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.72.9 59.1%   
Avg P/E ratio x18.2-11.5 -158.8%  
P/CF ratio (eoy) x13.5-13.9 -97.3%  
Price / Book Value ratio x3.03.7 81.6%  
Dividend payout %6.10-   
Avg Mkt Cap Rs m168,62545,182 373.2%   
No. of employees `00012.04.3 280.4%   
Total wages/salary Rs m20,5612,836 725.1%   
Avg. sales/employee Rs Th8,196.03,637.5 225.3%   
Avg. wages/employee Rs Th1,708.1660.5 258.6%   
Avg. net profit/employee Rs Th768.5-916.6 -83.8%   
INCOME DATA
Net Sales Rs m98,65515,616 631.8%  
Other income Rs m2,081109 1,903.4%   
Total revenues Rs m100,73615,725 640.6%   
Gross profit Rs m15,858-2,706 -586.0%  
Depreciation Rs m3,259674 483.6%   
Interest Rs m3,346423 791.0%   
Profit before tax Rs m11,335-3,694 -306.9%   
Minority Interest Rs m0-10 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,756231 1,627.5%   
Profit after tax Rs m9,250-3,935 -235.1%  
Gross profit margin %16.1-17.3 -92.8%  
Effective tax rate %33.1-6.2 -530.4%   
Net profit margin %9.4-25.2 -37.2%  
BALANCE SHEET DATA
Current assets Rs m66,96811,437 585.5%   
Current liabilities Rs m40,2116,435 624.9%   
Net working cap to sales %27.132.0 84.7%  
Current ratio x1.71.8 93.7%  
Inventory Days Days83111 75.1%  
Debtors Days Days81124 65.5%  
Net fixed assets Rs m33,3226,667 499.8%   
Share capital Rs m28273 389.2%   
"Free" reserves Rs m55,7700-   
Net worth Rs m56,05212,257 457.3%   
Long term debt Rs m35,7384,307 829.7%   
Total assets Rs m132,88823,154 573.9%  
Interest coverage x4.4-7.7 -56.7%   
Debt to equity ratio x0.60.4 181.4%  
Sales to assets ratio x0.70.7 110.1%   
Return on assets %9.5-15.2 -62.5%  
Return on equity %16.5-32.1 -51.4%  
Return on capital %17.8-19.8 -89.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m40,1400-   
CASH FLOW
From Operations Rs m13,2421,333 993.4%  
From Investments Rs m-6,990-409 1,707.9%  
From Financial Activity Rs m-7,3873,909 -189.0%  
Net Cashflow Rs m-2,9714,833 -61.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.29 Rs / ZAR

Compare GLENMARK PHARMA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: ORCHID PHARMA LTD  IPCA LABS  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  STERLING BIOTECH  



Today's Market

Volatile Day for Indian Indices: Sensex Ends 131 Points Lower Post Rebound; Telecom and Auto Stocks Bleed(Closing)

It was a volatile day for India share markets today. The benchmark indices opened higher but turned volatile.

Related Views On News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus (Profit Hunter)

Mar 17, 2020

If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It. (Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World (The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon (Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

How to Trade the Coronavirus Crash - Download this FREE Report Now
How to Profit Even During These Times of Crisis: Vijay Bhambwani Reveals his Strategy...
The Best Stocks For 2020 - How to Spot Multibagger Ideas. FREE Sign up!
Free Report: The Secret to Increasing Your Trading Profits Daily!
Find Out Our Top 7 Bluechips for 2020 Virtually FREE. Click Here Now!

GLENMARK PHARMA SHARE PRICE


Mar 27, 2020 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - DISHMAN PHARMA COMPARISON

COMPARE GLENMARK PHARMA WITH

OTHER USEFUL LINKS

MARKET STATS